On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk”) ...
A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...
ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
MyChesCo on MSN
FDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for Millions Battling Diabetes
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first ...
On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and pediatric diabetic patients. The subcutaneous medication is approved in a 3 milliliter, ...
Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with ...
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...
DUBLIN--(BUSINESS WIRE)--The "Global Rapid Acting Insulin Market By Product Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" ...
(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its approval ...
Rise in availability of continuous glucose monitoring and surge in investments in R&D for human recombinant insulin drive the growth of the global rapid acting insulin market. PORTLAND, Ore., April 22 ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback